Puma Biotechnology (PBYI) Expected to Announce Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) is projected to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Puma Biotechnology to post earnings of $0.10 per share and revenue of $52.50 million for the quarter. Investors that wish to listen to the company's conference call can do so using this link.

Puma Biotechnology Price Performance

Shares of PBYI stock traded down $0.02 during mid-day trading on Friday, hitting $2.90. 483,640 shares of the stock were exchanged, compared to its average volume of 535,051. Puma Biotechnology has a 52-week low of $2.22 and a 52-week high of $7.15. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The company has a market cap of $142.36 million, a PE ratio of 6.04 and a beta of 1.09. The firm has a fifty day moving average of $3.00 and a 200 day moving average of $2.89.

Insider Transactions at Puma Biotechnology

In related news, CEO Alan H. Auerbach sold 33,841 shares of Puma Biotechnology stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now directly owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. The trade was a 0.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the transaction, the insider now directly owns 108,951 shares of the company's stock, valued at $343,195.65. The trade was a 7.97 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 23.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PBYI. StockNews.com lowered Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Friday, December 6th. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Monday, December 23rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.